Another 1c-SApNP Success
Science Advances publishes a proof-of-concept-paper
for nanoparticle HCV vaccine co-sponsored by NIH & UfovaxOur patented 1c-SApNP Platform Technology
has delivered promising vaccine candidates to address global health challenges
such as HIV, HCV, Ebola, RSV, Coronavirus, Malaria & Tuberculosis
Latest News
Publication entitled “Proof of concept forrational design of hepatitis C virus E2 core nanoparticle vaccines” in Science Advances.
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry, with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell–based HCV vaccine development through E2 optimization and nanoparticle display. We redesigned variable… [Read more]
News release by Scripps Research on the latest research paper on HCV vaccine co-sponsored by NIH and Ufovax
The new approach to vaccine design may also prove useful in developing a potential vaccine against the SARS-CoV-2 virus, which causes COVID-19. LA JOLLA, CA—A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a study… [Read more]
About Ufovax
Founded in early 2018, Ufovax, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.
Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.